Mounjaro®
Starting from £179.99/mo
Start journey Learn moreA strange, bitter or metallic taste in the mouth is a recognised side effect of semaglutide (Wegovy), reported by a meaningful proportion of participants in the STEP clinical trial programme. It tends to appear early in treatment, often after starting or increasing a dose, and for most people it fades within days to a couple of weeks. It is uncomfortable, but it is not a sign that something has gone seriously wrong. Like most of Wegovy's side effects, the taste disturbance sits within a broader pattern of gastrointestinal and sensory changes that semaglutide can cause as your body adjusts — and it is worth understanding what is driving it before deciding whether to ride it out or speak to your prescriber. As a prescription-only medicine, Wegovy requires clinical assessment before treatment begins and ongoing clinical oversight throughout, so any side effect that worries you is worth raising with your care team rather than managing alone.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults with obesity over 68 weeks and produced the evidence base that supports Wegovy's UK licence. Alongside the headline weight-reduction figures, the trial recorded a cluster of gastrointestinal side effects (nausea, diarrhoea, vomiting, constipation) that are now familiar to most people on this medicine. Taste disturbance was captured within the broader sensory and GI adverse-event profile. It is not the most common complaint, but it appears frequently enough to feature in the NHS medicines information for semaglutide as a recognised effect.
The timing matters. Most people who report a horrible or strange taste on Wegovy notice it in the first few days after a new pen or a dose step up. That mirrors the pattern seen with other GLP-1 side effects: the body is responding to a sharp rise in drug exposure, and the sensory system is part of that response. The taste usually softens within one to two weeks at the same dose. Participants in the STEP programme who completed titration generally reported that these early-stage effects became less intrusive over time.
There is a practical reason to name this clearly: people who do not know that taste changes are expected sometimes assume the sensation signals an allergy, a dental problem, or that something has gone wrong with the medicine. In the vast majority of cases, it is none of those things. It is biology.
Semaglutide activates GLP-1 receptors, which are found throughout the gut and also in the brain, salivary glands and taste-receptor cells. When those receptors are stimulated, saliva production can shift in volume or composition, and the acidity of the upper GI tract changes. Both factors affect how food and drink register on the tongue. The result can be anything from a mild metallic edge to a persistently bad taste in the mouth on Wegovy that lingers between meals.
Slowed gastric emptying (one of the core mechanisms through which semaglutide reduces appetite) also plays a role. When food sits in the stomach longer than usual, the interplay between digestive acids and the oral environment can produce an unpleasant reflux-like taste that rises without the person feeling overtly sick. This is why the taste can seem worse in the morning, on an empty stomach, or after eating fatty foods that take longer to digest.
Some people describe the sensation as an unexpected sweetness rather than bitterness or metal. That, too, is a documented variant, GLP-1 receptors are present in sweet-taste receptor cells, and their activation can subtly alter sweetness perception. The distortion is real, even when it seems at odds with what you expect a side effect to feel like.
There is no single fix, but several things consistently help, based on what is understood about the mechanism. Staying well hydrated keeps saliva flowing and dilutes the acidic environment that can sharpen a metallic taste. Small, frequent meals (particularly lower-fat options in the first week after a dose increase) put less demand on slowed gastric emptying. Rinsing your mouth with water after eating, and brushing with a mild toothpaste rather than a strongly flavoured one, can reduce the background sensation without overwhelming already-sensitive taste buds.
Cold or room-temperature foods are often more palatable than hot ones when taste is distorted. Some people find that sucking ice chips or eating bland, plain foods for a few days gives the adjustment period a chance to pass. These are not medically prescribed strategies; they are practical adjustments that align with what is known about why the taste occurs.
If you are comparing how different semaglutide experiences feel (or wondering whether oral versus injectable forms affect this differently) you may find the broader guide to mouth-related side effects of Wegovy useful reading. And for a wider look at the treatment itself, the Wegovy overview page covers the full picture of how semaglutide works and what to expect.
A taste that is unpleasant but fading is a nuisance, not a red flag. A taste that is worsening, accompanied by severe stomach pain that reaches your back, or paired with vomiting you cannot manage, is different. In January 2026 the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent but serious risk with GLP-1 medicines; the hallmark symptom is severe, persistent abdominal pain that may spread to the back, sometimes accompanied by nausea and vomiting. If that describes your experience, seek urgent medical attention rather than waiting for a prescriber appointment.
Taste disturbance alone, without any of those accompanying features, does not require urgent care. It does, however, warrant a conversation with your prescriber if it is severe enough to affect your eating, is making it difficult to stay hydrated, or simply is not improving after two to three weeks at the same dose. Adjusting the titration pace is one of the tools available; your prescriber can guide that based on your specific situation.
If you are still working out whether Wegovy is the right fit for you, or weighing it against other options, a look at how semaglutide is used for weight management in the UK gives useful context on both the licensed indications and the clinical pathway. For anyone considering starting treatment, our free consultation connects you with a GPhC-registered prescriber who can review your history and answer exactly this kind of question.
On the cost side, if you are researching what private treatment involves, the Wegovy price comparison guide for the UK explains honestly what is included in a legitimate private prescription service, consultation, prescription, clinical review, delivery. At nume, your consultation is free, every repeat order is reviewed by a real prescriber, and your treatment arrives via DPD in plain, unmarked packaging with a tracking link sent to your phone. There are no subscriptions and no hidden charges.
If you have questions that are not covered here, you are always welcome to get in touch with our team, or browse the general FAQs for quick answers.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.